1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62C015633863EC5CF652582DD002883EE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/best-practices-communicating-disseminating-medical-information-external-stakeholders
18
19
2018.204.48.40
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Medical Communication

Best Practices in Communicating and Disseminating Medical Information to External Stakeholders

ID: POP-297


Features:

19 Info Graphics

28 Data Graphics

650+ Metrics

9 Narratives

14 Best Practices


Pages: 56


Published: 2018


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
The Medical Information function within pharmaceutical, biotechnology and medical device companies is responsible for disseminating critical and diverse information to key external stakeholders such as HCPs, payers, formulary decision makers, clinical investigators, contracted HCP speakers, and government agencies.

To increase efficiency and ensure consistency in meeting the informational needs of these stakeholders, strong Medical Information groups have developed and leverage a wide range of effective communication tools and approaches. Best Practices, LLC undertook this benchmarking research to examine how these top Medical Information teams within leading organizations disseminate on and off-label information to external stakeholders for maximum impact.

This report uncovers insights around the types of information shared with different stakeholders, effective channels used for information distribution, proactive vs. reactive sharing, and critical measures taken to protect inadvertent use of information within slide decks and other medical information assets. This report also highlights best practices in distributing slide decks to external stakeholders.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Manufacturing; Consumer Products; Medical Device; Laboratories


Companies Profiled:
Abbott; AbbVie; Amicus Therapeutics; Bayer; Boehringer Ingelheim; BTG plc; CSL Behring; Depomed; Eisai; EMD Serono; Enlyton; Glenmark; GRAIL; Grifols; Jazz Pharmaceuticals; Juno Therapeutics; Medtronic; Merck; Merz Pharma; Novartis; Novo Nordisk; Pfizer; Pierre Fabre; Santen; Shire; Vifor Pharma

Study Snapshot

Best Practices, LLC engaged 31 medical information professionals from 26 leading companies in this benchmarking research. Research analysis and recommendations are presented into two segments: Large Companies Segment and Small-Mid Sized Companies Segment.

Key topics covered in this report include:

  • Methods of distribution used to disseminate information
  • Types of information shared with different stakeholders
  • Protection of medical information assets
  • Best practices in distributing slide decks to external stakeholders


Key Findings

Sample key insights uncovered from this report are noted below. Detailed findings are available in the full report.

1. Most Medical Information Provided to Stakeholders Reactively:
  • Medical Information groups send slide decks in a reactive manner following an unsolicited request, specifically asking for slide decks on a particular topic.
  • Off-label information is communicated reactively, typically in PDF format.
  • Slide decks may be generated to handle frequently asked questions.

2. HCPs Seen as Core Stakeholder Served, Others Growing:
  • About 75% of companies provide medical information to thought leaders, and more than half do so to clinical investigators.
  • While a minority shares information with payers and formulary decision-makers, the growing importance of these groups would suggest that the number of companies providing data will grow in upcoming years.

Table of Contents

I.
Executive Summary: Insights, Opportunities & Analysispp 3-6
Summary findingsp. 4
Benchmark classp. 5
Segmentationp. 6
II.
Distribution of Medical Informationpp 7-25
Criteria to determine the type of information to be shared
Type of pipeline information to be shared
Recipient stakeholder groups
Factors considered before distributing the information
Methods of distributing the information
III.
Protecting Medical Informationpp 26-29
Types of protections used for slide decks
Locking slide decks
IV.
Best Practicespp 30-32
Best practices in distributing slide decks
V.
Participant Demographicspp 33-36
Participant title
Therapeutic areas
Geographic span
VI.
Appendixpp 37-55

    List of Charts & Exhibits

    I. Distribution of Medical Information
    • Use of slide decks for communicating off-label information to HCPs and other stakeholders
    • Determination of the kind of off-label information that can be provided in a slide-deck format
    • Criteria used to determine whether medical information is to be provided in PPT or PDF format
    • Type of pipeline information provided via slide decks
    • Stakeholder groups receiving medical information slide decks
    • Information commonly shared with HCPs by large and small/mid-sized companies
    • Information commonly shared with payers by large and small/mid-sized companies
    • Information commonly shared with formulary decision makers by large and small/mid-sized companies
    • Information commonly shared with clinical investigators by large and small/mid-sized companies
    • Information commonly shared with contracted HCP speakers by large and small/mid-sized companies
    • Information commonly shared with government agencies by large and small/mid-sized companies
    • Takeaways of proactive vs. reactive sharing
    • Type of information and stakeholder groups with whom medical information is shared proactively
    • Type of information and stakeholder groups with whom medical information is shared reactively
    • Information types sent via. slide decks
    • Executive insights on proactive and reactive information sharing
    • Most important internal and external factors influencing the use of slide decks for sharing information with external stakeholders
    • Methods used to disseminate information and slide decks

    II. Protecting Medical Information
    • Types of protection used for slide decks and other medical information assets
    • Use of locked vs. editable medical information slide decks
    • Reasons for using locked or editable medical information slide decks

    III. Best Practices
    • Best practices in distributing slide decks to external stakeholders – Communicating reactively, and coordination with internal review functions
    • Best practices in distributing slide decks to external stakeholders – Quality of information and alignment with stakeholder needs, and protection against inadvertent use

    IV. Participant Demographics
    • Role of benchmark partners
    • Therapeutic areas represented by benchmark companies
    • Benchmark partners’ geographic span of responsibility

    V. Appendix
    • Type of information shared in proactive or /and reactive manner with HCPs and clinical investigators within small/mid-sized companies
    • Type of information shared in proactive or /and reactive manner with formulary decision makers and payers (non-HCPs) within small/mid-sized companies
    • Type of information shared in proactive or /and reactive manner with contracted HCP speakers and government agencies within small/mid-sized companies
    • Type of information shared in proactive or /and reactive manner with HCPs and clinical investigators within large companies
    • Type of information shared in proactive or /and reactive manner with formulary decision makers and payers (non-HCPs) within large companies
    • Type of information shared in proactive or /and reactive manner with contracted HCP speakers and government agencies within large companies
    • Communication with HCPs at small/mid-sized companies
    • Communication with payers at small/mid-sized companies
    • Communication with formulary decision makers at small/mid-sized companies
    • Communication with clinical investigators at small/mid-sized companies
    • Communication with contracted HCP speakers at small/mid-sized companies
    • Communication with government agencies at small/mid-sized companies
    • Communication with HCPs at large companies
    • Communication with payers at large companies
    • Communication with formulary decision makers at large companies
    • Communication with clinical investigators at large companies
    • Communication with contracted HCP speakers at large companies
    • Communication with government agencies at large companies